Soucier Richard, Silverman David, Abordo Melecio, Jaagosild Priit, Abiose Ademola, Madhusoodanan K P, Therrien Michael, Lippman Neal, Dalamagas Honora, Berns Ellison
The Hoffman Heart Institute of Connecticut, Saint Francis Hospital and Medical Center, Hartford CT 06105, USA.
Med Sci Monit. 2003 Mar;9(3):PI19-23.
It is unclear whether acute conversion of atrial fibrillation (AF) with anti-arrhythmic drugs following cardiac surgery restores and/or maintains sinus rhythm or reduces hospital length of stay (LOS).
MATERIAL/METHODS: A randomized prospective pilot study was conducted in 2 teaching hospitals from 3/28/98 to 8/2/99 to study the effect of the early use of ibutilide or propafenone on the duration of AF, rhythm at discharge, and LOS. A total of 42 stable patients with new AF after surgery were randomized to oral propafenone (600mg, single dose; n=20), ibutilide (1 mg up to 2 doses if necessary; n=10), or rate control only (n=12). Agents used for rate control were left to the discretion of the primary physician but beta-blockers were encouraged.
Pre-randomization distribution of diabetes, CHF, previous AF, and the use of beta-blockers were similar in all groups. At 24 hours 0%, 65% and 34% of patients in the ibutilide (p=0.01), propafenone (p=ns), and rate control groups respectively remained in AF. Although ibutilide decreased AF duration, recurrence rates were 90%, 41%, and 58% in those groups (p=ns compared to rate control). Of the 3 patients who did not convert, all received propafenone. There was no difference in LOS or rhythm at discharge.
Ibutilide but not propafenone decreases the duration of AF after cardiac surgery and neither appears to affect LOS or rhythm at discharge. This data suggests that post operative AF is transient and routine anti-arrhythmic therapy is not necessary for the majority of patients.
心脏手术后使用抗心律失常药物使房颤(AF)急性转复是否能恢复和/或维持窦性心律,或缩短住院时间(LOS)尚不清楚。
材料/方法:1998年3月28日至1999年8月2日在2家教学医院进行了一项随机前瞻性试验研究,以探讨早期使用伊布利特或普罗帕酮对房颤持续时间、出院时心律及住院时间的影响。共有42例心脏手术后新发房颤的稳定患者被随机分为口服普罗帕酮组(600mg,单次剂量;n = 20)、伊布利特组(必要时1mg,最多2剂;n = 10)或仅进行心率控制组(n = 12)。用于心率控制的药物由主治医师决定,但鼓励使用β受体阻滞剂。
所有组中糖尿病、充血性心力衰竭(CHF)、既往房颤及β受体阻滞剂使用情况的随机分组前分布相似。24小时时,伊布利特组、普罗帕酮组和心率控制组分别有0%、65%和34%的患者仍处于房颤状态(伊布利特组p = 0.01,普罗帕酮组p = 无统计学意义)。尽管伊布利特缩短了房颤持续时间,但这些组的复发率分别为90%、41%和58%(与心率控制组相比p = 无统计学意义)。在未转复的3例患者中,均接受了普罗帕酮治疗。住院时间或出院时心律无差异。
伊布利特而非普罗帕酮可缩短心脏手术后房颤的持续时间,且两者似乎均不影响住院时间或出院时心律。该数据表明术后房颤是短暂的,大多数患者无需常规抗心律失常治疗。